title: Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients.
abstract: OBJECTIVE
  To assess the effect of megestrol acetate (MA), a progestational appetite stimulant commonly used in patients with AIDS and cancer, on body weight and composition, respiratory muscle strength, arterial blood gas levels, and subjective perceptions in COPD patients.
  
  
  METHODS
  Prospective, double-blind, randomized, placebo-controlled trial conducted on an outpatient basis at 18 sites.
  
  
  METHODS
  Underweight (< 95% ideal body weight) COPD patients > or = 40 years old.
  
  
  METHODS
  Either MA, 800 mg/d oral suspension, or placebo at a 1:1 ratio for 8 weeks.
  
  
  RESULTS
  Of 145 randomized patients (63% men), 128 patients completed the trial. Body weight increased by 3.2 kg in the MA group and 0.7 kg in the placebo group (p < 0.001). Anthropometric and dual-energy radiograph absorptiometry assessments confirmed that weight gain was mainly fat. Spirometry and maximal voluntary ventilation showed no significant changes from baseline in either group, and the difference in the change in maximum inspiratory pressure between groups was not significant. The 6-min walk distances did not differ statistically between groups at week 2 and week 4, but were greater in the placebo group at week 8 (p = 0.012). Consistent with the known ability of MA to stimulate ventilation, PaCO(2) decreased (4.6 mm Hg, p < 0.001) and PaO(2) increased (2.8 mm Hg, p < 0.04) in the MA group. Questionnaires revealed that body image and appetite improved in the MA group but not the placebo group. Adverse event frequency and type were similar in both groups, but cortisol and testosterone (in men) levels decreased substantially in the MA group.
  
  
  CONCLUSIONS
  We conclude that MA safely increased appetite and body weight, stimulated ventilation, and improved body image in underweight COPD patients, but did not improve respiratory muscle function or exercise tolerance.
authors.affiliation: Nova Southeastern University College of Osteopathic Medicine, Fort Lauderdale, FL, USA. Jeffrey@nova.edu
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Weisberg
authors.forename: Jack
authors.initials: J
authors.lastname: Wanger
authors.forename: Jeffery
authors.initials: J
authors.lastname: Olson
authors.forename: Barry
authors.initials: B
authors.lastname: Streit
authors.forename: Charles
authors.initials: C
authors.lastname: Fogarty
authors.forename: Thomas
authors.initials: T
authors.lastname: Martin
authors.forename: Richard
authors.initials: R
authors.lastname: Casaburi
mesh_terms: D000368:Aged; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D019290:Megestrol Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D011446:Prospective Studies; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D013851:Thinness / Q000188:drug therapy*; D014797:Vital Capacity / Q000187:drug effects; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D019290:Megestrol Acetate